• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[乳腺癌短期使用他莫昔芬和氯烯雌醚后的类固醇激素受体与细胞增殖活性]

[Steroid hormone receptors and cellular proliferative activity following the short-term use of tamoxifen and chlorotrianisene in breast cancer].

作者信息

Vyshinskaia G V, Murav'eva N I, Shelsputina Z F, Kuz'mina Z V, Nikolaeva T G

出版信息

Eksp Onkol. 1985;7(5):66-8.

PMID:4065023
Abstract

The content of estrogen receptors (ER), progesterone receptors (PR), the proliferative pool level in the tumour tissue were investigated in 6 patients with the disseminated breast tumour before and after 9-day treatment with tamoxifen and chlorotrianisene for intensification of the effect of cytostatic preparations. A significant increase of the DNA synthesis intensity and proliferative pool value is observed in ER+ tumours of 2 patients. An increase of the PR level in tumour biopsies was registered in 2 patients. A decrease of the ER+ level was detected in ER+ tumours in all three patients.

摘要

对6例播散性乳腺癌患者在使用他莫昔芬和氯烯雌醚进行为期9天的治疗前后，研究了肿瘤组织中雌激素受体（ER）、孕激素受体（PR）的含量以及增殖池水平，以增强细胞抑制制剂的效果。在2例ER阳性肿瘤患者中观察到DNA合成强度和增殖池值显著增加。2例患者的肿瘤活检中PR水平升高。在所有3例患者的ER阳性肿瘤中均检测到ER阳性水平降低。

相似文献

1
[Steroid hormone receptors and cellular proliferative activity following the short-term use of tamoxifen and chlorotrianisene in breast cancer].[乳腺癌短期使用他莫昔芬和氯烯雌醚后的类固醇激素受体与细胞增殖活性]
Eksp Onkol. 1985;7(5):66-8.
2
Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer.伊拉克晚期乳腺癌患者对他莫昔芬反应的评估。
East Mediterr Health J. 2000 Mar-May;6(2-3):475-82.
3
Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.他莫昔芬对子宫内膜癌类固醇激素受体、激素浓度的影响及流式细胞术DNA分析结果
Gynecol Oncol. 1999 Mar;72(3):331-6. doi: 10.1006/gyno.1998.5281.
4
[Tamoxifen-induced progesterone receptors in breast tumors].
Vopr Onkol. 1991;37(9-10):916-21.
5
[Rational combinations of hormonal and cytostatic agents in disseminated forms of breast cancer].
Vopr Onkol. 1987;33(11):13-7.
6
Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.接受他莫昔芬和孕激素治疗的绝经后乳腺癌患者子宫内膜中的雌激素和孕激素受体
Gynecol Oncol. 1997 Apr;65(1):83-8. doi: 10.1006/gyno.1996.4595.
7
Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PgR and AR) in patients with primary breast cancer.他莫昔芬对原发性乳腺癌患者类固醇激素受体（雌激素受体、孕激素受体和雄激素受体）肿瘤含量的影响。
Anticancer Res. 1994 May-Jun;14(3B):1313-6.
8
[The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].[类固醇受体对乳腺癌患者预后及激素治疗的重要性：荷兰东南部的一项回顾性研究]
Ned Tijdschr Geneeskd. 1998 Aug 1;142(31):1772-8.
9
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.包括雌激素受体（ER）、孕激素受体（PR）、Bcl-2和胰岛素样生长因子-1受体（IGF-IR）在内的雌激素受体活性谱，可能有潜力作为晚期乳腺癌患者来曲唑或他莫昔芬治疗的选择标准。
Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383.
10
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.雌激素受体阳性、孕激素受体阴性乳腺癌：与生长因子受体表达及他莫昔芬耐药性的关联
J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61. doi: 10.1093/jnci/dji249.